SCHEMBL12469049

SCHEMBL12469049

c1ccc(-n2nnnc2SCCN2CCN(c3cccc4ccccc34)CC2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.48
MAPT P10636 3/20 0.48
LMNA P02545 2/20 0.48
ADRB2 P07550 1/20 0.47
SMN1; SMN2 Q16637 4/20 0.46
TSHR P16473 3/20 0.46
NPC1 O15118 1/20 0.46
NFKB1 P19838 1/20 0.46
RAB9A P51151 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
POLB P06746 1/20 0.46
HPGD P15428 2/20 0.46
APOBEC3A P31941 1/20 0.46
APOBEC3G Q9HC16 1/20 0.46
HSD17B10 Q99714 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12469226 0.94 ALDH1A1 (0.48) ALDH1A1MAPTLMNAADRB2TSHR
SCHEMBL12469487 0.84 SLC6A2 (0.52) ALDH1A1MAPTLMNASMN1; SMN2TSHR
SCHEMBL12469234 0.80 ALDH1A1 (0.61) ALDH1A1MAPTLMNAL3MBTL1POLB
SCHEMBL12469501 0.78 DRD2 (0.58) ALDH1A1LMNATSHRPOLBHPGD
SCHEMBL12469526 0.77 NPSR1 (0.63) ALDH1A1MAPTSMN1; SMN2TSHRNFKB1
SCHEMBL12469411 0.77 SLC6A2 (0.52) ALDH1A1MAPTLMNASMN1; SMN2TSHR
SCHEMBL13711982 0.75 DRD3 (0.60) ALDH1A1MAPTTSHRNFKB1TDP1
SCHEMBL12468792 0.75 HPGD (0.47) NPC1RAB9AHPGD
SCHEMBL12469400 0.74 ALDH1A1 (0.44) ALDH1A1MAPTLMNASMN1; SMN2TSHR
SCHEMBL12469002 0.74 ALDH1A1 (0.58) ALDH1A1LMNATSHRL3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130289047-A1 HETEROARYLTHIO DERIVATIVES AND ANALOGUES EPIOMED THERAPEUTICS, INC. (US) 2013-10-31 US disclosed
WO-2012051601-A2 HETEROARYLTHIO COMPOUNDS EPIOMED THERAPEUTICS, INC. (US) 2012-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130289047-A1 HETEROARYLTHIO DERIVATIVES AND ANALOGUES NLN, HTT, ABAT ALDH1A1 2297/4885MAPT 5/4885LMNA 2984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.